-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 12, according to the official website of CDE, Jiangsu Wanbang Pharmaceutical’s 4 new drug Ochinib mesylate was declared for marketing (acceptance number: CYHS2101145).
Osimertinib is the third-generation oral and irreversible selective EGFR mutation inhibitor developed by AstraZeneca.
In March 2017, the National Medical Products Administration (NMPA) approved the third-generation lung cancer targeted drug Teresa® (osimertinib mesylate tablets, AZD9291) for the past transepidermal growth factor receptor (EGFR) tyrosine Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have disease progression during or after treatment with TKI, and confirmed to have EGFR T790M mutation-positive.
In October 2018, osimertinib mesylate entered the national medical insurance list through special negotiations on the access of anti-cancer drug medical insurance.
However, the Insight database shows that Ochinib's compound patent (CN 103702990) will not expire in China until 2032, which is still far away.
In addition, the current domestic three-generation EGFR-TKI has been fiercely competitive.
From the Insight database (http://db.
